Stirring on the hepatitis C front

For years, interferon alpha, and more recently consensus interferon from Amgen Inc., have been about the only treatments for hepatitis C. None are terribly effective and all have side effects, making the area an attractive one for new players.

Among new developments reported last week were clinical progress by Isis Pharmaceuticals Inc. and ViroPharma Inc., as well as discovery of a candidate vaccine by Epimmune Inc.

Read the full 654 word article

How to gain access

Continue reading with a
two-week free trial.